Table of Contents
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 8, 2001
AVIGEN, INC.
Delaware
(State or other jurisdiction of incorporation)
| 000-28272 | 13-3647113 | |
| (Commission File No.) | (IRS Employer Identification No.) |
1301 Harbor Bay Parkway
Alameda, California 94502
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code:(510) 748-7150
| ITEM 5. OTHER EVENTS | ||||||||
| ITEM 7. EXHIBITS | ||||||||
| SIGNATURE | ||||||||
| EXHIBIT INDEX | ||||||||
| EXHIBIT 99.1 | ||||||||
ITEM 5. OTHER EVENTS
On October 8, 2001, Avigen, Inc. announced that that the clinical trial studying the safety of its Coagulin-B™ gene therapy for the treatment of hemophilia B is on clinical hold. A copy of this press release is attached as Exhibit 99.1 hereto.
ITEM 7. EXHIBITS
Exhibit 99.1. Press Release Dated October 8, 2001.
2.
Table of Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AVIGEN, INC. | ||
| Dated: October 9, 2001 | By: | /s/ Thomas J. Paulson |
| Thomas J. Paulson Vice President, Finance and Chief Financial Officer | ||
3.
Table of Contents
EXHIBIT INDEX
| Exhibit | ||
| 99.1. | Press Release Dated October 8, 2001. |
4.